

C1 3. (Amended) A method for inducing sensitivity to a chemotherapeutic agent in an individual in vivo comprising administering to said individual a composition comprising a RAD51 antisense molecule thereby inducing said sensitivity to a chemotherapeutic agent.

4. (Amended) A method for inhibiting the growth of a cancerous cell comprising administering to said cell a composition comprising a RAD51 antisense molecule thereby inhibiting said growth of a cancerous cell.

C2 5. (Amended) A method for inducing sensitivity to radiation in a cancerous cell comprising administering to said cell a composition comprising RAD51 antisense molecule thereby inducing said sensitivity to radiation.

6. (Amended) A method for inducing sensitivity to a chemotherapeutic agent in a cancerous cell comprising administering to said cell a composition comprising RAD51 antisense molecule thereby inducing said sensitivity to a chemotherapeutic agent.

N.E. 8. The method of Claim 1 further comprising the step of administering radiation.

C3 9. (Amended) A method of prolonging the survival of an individual comprising administration to said individual a RAD51 antisense molecule thereby prolonging said survival.

10. (Amended) A method of treating cancer in an individual comprising administration to said individual a RAD51 antisense molecule thereby treating said cancer in an individual.

C4 11. (Amended) A method according to claim 10 wherein said administration comprises localized delivery of said RAD51 antisense molecule to a cancerous or potentially cancerous site.

12. (Amended) A method according to claim 11 wherein said method further comprises radiation treatment at said site.

13. (Amended) A method according to claim 11 wherein said method further comprises chemotherapeutic treatment of said patient.

N.E. 15. The method of Claim 1, wherein said administering is locally to a site wherein said cell proliferation is to be inhibited.

16. The method of Claim 15, wherein said administering is by injection.

C5 17. (Amended) The method of Claim 15, wherein said site is a tumor.

N.E. 18. The method of Claim 2, wherein said administering is locally to a site wherein said sensitivity is to be induced.

19. The method of Claim 18, wherein said administering is by injection.

C6 20. (Amended) The method of Claim 18, wherein said site is a tumor.

N.E. 21. The method of Claim 3, wherein said administering is locally to a site wherein said sensitivity is to be induced.